Multifunctional Polymeric Micelles Co-loaded with Anti–Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2015-02-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-14-0556PMID 25657335PMCID PMC4394040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.

  2014cited by this paper
• Morphine Induces Redox-Based Changes in Global DNA Methylation and Retrotransposon Transcription by Inhibition of Excitatory Amino Acid Transporter Type 3–Mediated Cysteine Uptake

  2014cited by this paper
• Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.

  2014cited by this paper
• Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

  2014cited by this paper
• Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer

  2014cited by this paper
• Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.

  2014influential reference
• siRNA delivery: from basics to therapeutic applications.

  2013cited by this paper
• Prognostic value of survivin expression in breast cancer patients: a meta-analysis

  2013cited by this paper
• Survivin Status Affects Prognosis and Chemosensitivity in Epithelial Ovarian Cancer

  2013cited by this paper
• New Strategy for Overcoming Resistance to Chemotherapy of Ovarian Cancer

  2013cited by this paper
• Survivin in Solid Tumors: Rationale for Development of Inhibitors

  2012cited by this paper
• Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly.

  2012cited by this paper
• Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts

  2012cited by this paper
• Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions.

  2012cited by this paper
• Effect of shRNA targeting survivin on ovarian cancer

  2012cited by this paper
• Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

  2011cited by this paper
• Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

  2010cited by this paper
• Effective stabilization and delivery of siRNA: reversible siRNA-phospholipid conjugate in nanosized mixed polymeric micelles.

  2010cited by this paper
• Targeting survivin in cancer therapy

  2008cited by this paper
• Nanoparticle therapeutics: an emerging treatment modality for cancer

  2008cited by this paper
• Survivin, cancer networks and pathway-directed drug discovery

  2008cited by this paper
• YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

  2007cited by this paper
• Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells.

  2007cited by this paper
• Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters

  2005cited by this paper
• Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells

  2005cited by this paper
• A survivin gene signature predicts aggressive tumor

  2005cited by this paper
• Using mitochondrial DNA as a biosensor of early cancer development

  2005cited by this paper
• Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines

  2005cited by this paper
• A survivin gene signature predicts aggressive tumor behavior.

  2005cited by this paper
• Determination of subcutaneous tumor size in athymic (nude) mice

  2004cited by this paper
• Role of survivin and its splice variants in tumorigenesis

  2004influential reference
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Survivin is required for stable checkpoint activation in taxol-treated HeLa cells

  2003cited by this paper
• Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions.

  2002cited by this paper
• Paclitaxel and its formulations.

  2002cited by this paper
• A role for survivin in chemoresistance of endothelial cells mediated by VEGF

  2002cited by this paper
• Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer

  2002cited by this paper
• Urine detection of survivin and diagnosis of bladder cancer.

  2001cited by this paper
• In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy.

  2001cited by this paper
• Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor.

  1999cited by this paper
• A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

  1997cited by this paper
• Paclitaxel (taxol) for ovarian cancer.

  1993cited by this paper
• Hypersensitivity reactions from taxol.

  1990cited by this paper

• Strategies to Overcome Chemoresistance in Epithelial Ovarian Cancer: Navigating Beyond Challenges.

  2025cites this paper
• A review of RNA nanoparticles for drug/gene/protein delivery in advanced therapies: Current state and future prospects.

  2025cites this paper
• Ovarian cancer and its management through advanced drug delivery system

  2025cites this paper
• Nanoparticle-Mediated Delivery of siRNA: Targeting Gene Silencing in Cancer Therapy

  2025cites this paper
• Polymeric micelles: “magic bullets” for cancer treatment

  2025cites this paper
• Research Progress on Polymer-Based Nanocarriers for Tumor-Targeted Delivery of Survivin siRNA

  2025cites this paper
• Lipid nanoparticles for RNA delivery: Self-assembling vs driven-assembling strategies.

  2024cites this paper
• Micelle-engineered nanoplatforms for precision oncology

  2024cites this paper
• siRNA-based therapy for overcoming drug resistance in human solid tumours; molecular and immunological approaches.

  2024cites this paper
• Nanomedicine as potential cancer therapy via targeting dysregulated transcription factors.

  2023cites this paper
• Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases

  2023cites this paper
• Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

  2023cites this paper
• Targeting materials and strategies for RNA delivery

  2023cites this paper
• Nanocarriers for delivery of siRNA as gene silencing mediator

  2022cites this paper
• Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment

  2022cites this paper
• Applications of Nanotechnology-Based Approaches to Overcome Multi-Drug Resistance in Cancer.

  2022cites this paper
• Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal

  2022cites this paper
• Prognostic Value of Survivin in Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis

  2021cites this paper
• Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicine-Specific Cancer Targeting with Undetectable Toxicity.

  2021cites this paper
• Lignin, lipid, protein, hyaluronic acid, starch, cellulose, gum, pectin, alginate and chitosan-based nanomaterials for cancer nanotherapy: Challenges and opportunities.

  2021cites this paper
• Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy

  2021cites this paper
• The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy.

  2021cites this paper
• Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers

  2021cites this paper
• Responsive polymeric drug delivery systems for combination anticancer therapy: experimental design and computational insights

  2021cites this paper
• siRNA and Ovarian Cancer

  2021cites this paper
• The Pharmacokinetics and Bio-distribution Studied by Simultaneous Analysis of Curcumin and Paclitaxel in Biosamples

  2021cites this paper
• Emerging Gene Knockdown Technology Using Small Interfering RNA in Ovarian Cancer

  2021cites this paper
• Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers

  2021cites this paper
• Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer.

  2021cites this paper
• Applications and Limitations of Dendrimers in Biomedicine

  2020cites this paper
• Micelleplexes as nucleic acid delivery systems for cancer-targeted therapies.

  2020cites this paper
• Mesenchymal Stem Cells As Guideposts for Nanoparticle-Mediated Targeted Drug Delivery in Ovarian Cancer

  2020cites this paper
• Chimeric siRNA-DNA Surfactants for the Enhanced Delivery and Sustained Cytotoxicity of a Gold(III) Metallodrug.

  2020cites this paper
• Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons

  2020cites this paper
• Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine

  2020cites this paper
• Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy

  2020cites this paper
• Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy.

  2020cites this paper
• National Cancer Institute Alliance for nanotechnology in cancer-Catalyzing research and translation toward novel cancer diagnostics and therapeutics.

  2019cites this paper
• Threatening cancer with nanoparticle aided combination oncotherapy

  2019cites this paper
• Surface-engineered polyethyleneimine-modified liposomes as novel carrier of siRNA and chemotherapeutics for combination treatment of drug-resistant cancers

  2019cites this paper
• Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

  2019cites this paper
• Stimuli-responsive polymeric micelles for extracellular and intracellular drug delivery

  2019cites this paper
• The Application of Biomaterials in the Treatment of Platinum‐Resistant Ovarian Cancer

  2019cites this paper
• Synthesis of Doxorubicin and miRNA Stimuli-Sensitive Conjugates for Combination Therapy.

  2019cites this paper
• NCI Alliance for Nanotechnology in Cancer – Catalysing Research and Translation Towards Novel Cancer Diagnostics and Therapeutics

  2019cites this paper
• Trace of survivin in cancer

  2019cites this paper
• Peptide-mediated delivery of therapeutic mRNA in ovarian cancer.

  2019cites this paper
• Practical approaches on the long-acting injections

  2019cites this paper
• Effect of chitosan based glycolipid‐like nanocarrier in prevention of developing acquired drug resistance in tri‐cycle treatment of breast cancer

  2019cites this paper
• Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article.

  2019cites this paper
• siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer

  2019cites this paper
• RNA Micelles for the Systemic Delivery of Anti-miRNA for Cancer Targeting and Inhibition without Ligand.

  2018cites this paper
• LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions.

  2018cites this paper
• Evaluation of the potential of a simplified co-delivery system with oligodeoxynucleotides as a drug carrier for enhanced antitumor effect

  2018cites this paper
• siRNA in ovarian cancer - Delivery strategies and targets for therapy.

  2018influential citation
• Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy.

  2018cites this paper
• Recent Progress in Gene Therapy for Ovarian Cancer

  2018cites this paper
• Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy

  2018cites this paper
• A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel

  2018cites this paper
• Recent insights into the development of nucleic acid-based nanoparticles for tumor-targeted drug delivery.

  2018cites this paper
• Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma

  2018cites this paper
• Thiol redox-sensitive cationic polymers for dual delivery of drug and gene.

  2018cites this paper
• Overcoming multiple drug resistance in cancer using polymeric micelles

  2018cites this paper
• Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer

  2018cites this paper
• SURFACE ENGINEERED PEI-MODIFIED LIPOSOMES FOR COMBINATION TREATMENT OF DRUG-RESISTANT CANCERS BY CO-DELIVERY OF siRNA AND PACLITAXEL

  2018cites this paper
• Polymeric micelles: Basic research to clinical practice.

  2017cites this paper
• Kuguacin J isolated from bitter melon leaves modulates paclitaxel sensitivity in drug-resistant human ovarian cancer cells

  2017cites this paper
• Targeted delivery of anticancer drugs: new trends in lipid nanocarriers

  2017cites this paper
• Positively Charged Combinatory Drug Delivery Systems against Multi-Drug-Resistant Breast Cancer: Beyond the Drug Combination.

  2017cites this paper
• A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin.

  2017cites this paper
• Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors

  2017cites this paper
• Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review

  2017cites this paper
• Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy

  2017cites this paper
• Smart micelleplexes as a new therapeutic approach for RNA delivery

  2017cites this paper
• Inhibitors of apoptosis: clinical implications in cancer

  2017cites this paper
• Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis.

  2017cites this paper
• Nanomedicine‐based combination anticancer therapy between nucleic acids and small‐molecular drugs☆

  2017cites this paper
• Local co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potential.

  2017cites this paper
• Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey.

  2016cites this paper
• Nanooncology in ovarian cancer treatment.

  2016cites this paper
• Combination Nanopreparations of a Novel Proapoptotic Drug – NCL-240, TRAIL and siRNA

  2016cites this paper
• Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer

  2016cites this paper
• Polycations and their biomedical applications

  2016cites this paper
• Polymer and Lipid-based Nanomedicine of Synergistic Drug Combination for Improving Chemotherapy of Multidrug Resistant Breast Cancer

  2016cites this paper
• Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles.

  2016cites this paper
• Low-dose radiation reverses cisplatin resistance in ovarian cancer cells by changing Survivin and Caspase-3 expression

  2016cites this paper
• Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy.

  2016cites this paper
• Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.

  2016cites this paper
• Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.

  2016cites this paper
• Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.

  2016cites this paper
• Micellar carriers for the delivery of multiple therapeutic agents.

  2015cites this paper
• Non-covalent Nanocomplexes of Folic Acid and Reducible Polyethylenimine for Survivin siRNA Delivery.

  2015cites this paper